Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award - PA - Bioinformatics and Computational Biology

University of Toronto

$105,000.00

A multi-omic approach to characterize gestational diabetes mellitus for predicting patient diagnosis at pregnancy onset and future transition to type II diabetes

FY 2023-24

Summary
Gestational diabetes mellitus (GDM) affects 1-14% of pregnancies worldwide, making it one of the most common metabolic disorders experienced during pregnancy. An estimated 35-50% of women who experience GDM go on to develop future type II diabetes mellitus (T2D) and are further at risk of other health complications, such as cardiovascular disease. Despite these high incidences, little is known about the transition of GDM to T2D and the biological processes underpinning these pathologies. Current means for diagnosing GDM and T2D heavily focus on blood glucose levels. Furthermore, a GDM test is typically administered at 24-28 weeks gestation. The development of new methods for accurately predicting GDM at pregnancy onset, as well as predicting future risk of T2D after a GDM pregnancy have the potential to vastly improve patient care, by facilitating earlier medical intervention and providing women with the necessary means to make informed decisions about their health. To develop these new methods, blood samples and medical histories from two study cohorts will be analyzed. The first is a cohort of 16,977 women who entered the study in their first pregnancy trimester and were monitored for GDM development. The second is a cohort of 1,035 women who experienced GDM and underwent follow-up for 12 years, monitoring for the development of T2D. The composition of proteins, lipids, and metabolites from their blood samples will be analyzed to identify biomarkers - a "molecular signature" - that can be used to create accurate tests for early GDM detection and future T2D risk. These biomarkers will also create a foundation for better understanding the biological mechanisms driving GDM and future T2D and have the potential to reveal novel putative therapeutic targets for treating these common metabolic disorders. The outcome of this research will be more knowledge of women's health and pregnancy and new tools to inform women on their health earlier than current medical standards.
Program
Doctoral Research Award - PA - Bioinformatics and Computational Biology
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
498320
Name
Hashimoto-Roth Emily
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
A multi-omic approach to characterize gestational diabetes mellitus for predicting patient diagnosis at pregnancy onset and future transition to type II diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA - Bioinformatics and Computational Biology
Keyworddelim
Biological Mechanisms; Biomarker Discovery; Computational Biology; Gestational Diabetes Mellitus; Insulin Resistance; Lipidomics; Machine Learning; Mass Spectrometry; Metabolomics; Proteomics
Abstract
Gestational diabetes mellitus (GDM) affects 1-14% of pregnancies worldwide, making it one of the most common metabolic disorders experienced during pregnancy. An estimated 35-50% of women who experience GDM go on to develop future type II diabetes mellitus (T2D) and are further at risk of other health complications, such as cardiovascular disease. Despite these high incidences, little is known about the transition of GDM to T2D and the biological processes underpinning these pathologies. Current means for diagnosing GDM and T2D heavily focus on blood glucose levels. Furthermore, a GDM test is typically administered at 24-28 weeks gestation. The development of new methods for accurately predicting GDM at pregnancy onset, as well as predicting future risk of T2D after a GDM pregnancy have the potential to vastly improve patient care, by facilitating earlier medical intervention and providing women with the necessary means to make informed decisions about their health. To develop these new methods, blood samples and medical histories from two study cohorts will be analyzed. The first is a cohort of 16,977 women who entered the study in their first pregnancy trimester and were monitored for GDM development. The second is a cohort of 1,035 women who experienced GDM and underwent follow-up for 12 years, monitoring for the development of T2D. The composition of proteins, lipids, and metabolites from their blood samples will be analyzed to identify biomarkers - a "molecular signature" - that can be used to create accurate tests for early GDM detection and future T2D risk. These biomarkers will also create a foundation for better understanding the biological mechanisms driving GDM and future T2D and have the potential to reveal novel putative therapeutic targets for treating these common metabolic disorders. The outcome of this research will be more knowledge of women's health and pregnancy and new tools to inform women on their health earlier than current medical standards.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hashimoto-Roth, Emily
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~